Article
14 Jul 2026
Harrow Re-Launches BYOOVIZ (Ranibizumab-nuna) In The United States
AUTHORS CONTENT
Article
01 Oct 2025
Recent International Biosimilar Regulatory Updates
Article
26 Apr 2024
Federal Circuit Dismisses Appeals In Regeneron v. Mylan (Aflibercept) BPCIA Litigation
Article
17 Jan 2024
Issue 43: PTAB Trial Tracker
Article
06 Mar 2023
Celltrion And Samsung File IPR Petitions On Aflibercept Patents
Article
31 Jan 2023
Celltrion Files IPR Petition On Aflibercept Patent
Article
05 Sep 2022
Outlook Therapeutics Re-Submits Its Ophthalmic Bevacizumab BLA
Article
08 Jul 2022
Fintiv 2.0: USPTO Director Issues Guidance Softening Risk Of Discretionary Denial
Article
19 May 2022
Alvotech Announces Positive Results From A Pharmacokinetic Similarity Study For Ustekinumab Biosimilar
Article
15 Apr 2022
FDA Accepts Regeneron And Sanofi's DUPIXENT (Dupilumab) SBLA For Priority Review